Connect with us

Market News

UTHR Stock Price Increased 14.99%: Here’s What Happened

Published

on

https://newsreportz.com/

The stock price of United Therapeutics ( NSDQ:UTHR ) increased by 16.54% on April 1, 2021. The price was pretty much stagnant throughout the day and rose from 167.27 USD to 192.34 USD. A rise of $25.07 occoured.

Therapeutics ( NSDQ:UTHR )  announced in a press release that they have got the FDA approval for Launch of Tyvaso®️ for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease.

“Adults living with both interstitial lung disease and pulmonary hypertension typically have a poor quality of life because of increased shortness of breath, poor exercise tolerance, and increased mortality. Until now, clinicians treating these patients did not have any approved treatment options,” said Aaron Waxman, M.D., Ph.D., Director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital and the chair of the INCREASE Study Steering Committee. “The regulatory approval of Tyvaso, an inhaled treatment, is exciting news both for patients with PH-ILD and the physicians who treat adults living with this serious, life-threatening disease. This will change the way we manage these patients.”

“With this approval representing such a breakthrough for PH-ILD patients, we’re treating this indication launch with a sense of urgency,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. ( NSDQ:UTHR ) “We’ve already expanded our field-based teams by 40% to educate the ILD community on the benefits of Tyvaso and how to properly diagnose PH-ILD. We expect rapid uptake of Tyvaso in this indication and expect to double the number of patients on Tyvaso therapy by the end of 2022, barring any COVID-related delays.”

A group of lung diseases in which marked scarring occurs within the lungs is called Interstitial lung disease (ILD). It is often complicated by pulmonary hypertension (PH; high blood pressure in the lungs), which further symptoms and decreases survival. PH is estimated to affect at least 15% of patients with early-stage ILD (approximately 30,000 PH-ILD patients in the United States) and may affect up to 86% of patients with more severe ILD.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Market News

BCRX’s Stock Price News: 11.29% Increase!

Published

on

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)’ stock price increased by 11.29% over the previous closing price, 10.19(April 14) and currently stands at 11.34. The volume on April 15 was pretty high, 8,433,333. Day’s range- 10.13 – 11.57. 

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)’s stock prices for the last 5 days-

Date Open High Low Close
Apr 15, 2021 10.31 11.58 10.13 11.34
Apr 14, 2021 9.79 10.64 9.72 10.19
Apr 13, 2021 9.59 9.73 9.23 9.69
Apr 12, 2021 10.15 10.16 9.34 9.50
Apr 09, 2021 10.38 10.56 10.19 10.21

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) yesterday announced that the Japanese National Health Insurance System (NHI) has approved the addition of oral, once-daily ORLADEYO™ (berotralstat) to the NHI drug price list on April 21, 2021.

Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan.

“Our goal is to bring ORLADEYO to HAE patients around the world who want a new oral, once-daily option to prevent their attacks. In Japan, ORLADEYO is the first approved prophylactic HAE medication, which has the potential to significantly impact the lives of HAE patients,” said Jon Stonehouse, president and chief executive officer of BioCryst.

The NHI price listing triggers a $15 million milestone payment from Torii to BioCryst. In addition, BioCryst will receive tiered royalties ranging from 20 percent to 40 percent of Japanese net sales.

About ORLADEYO™ (berotralstat)

ORLADEYO™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

Continue Reading

Market News

BTG Stock Price News: 6.41% Increase

Published

on

B2Gold Corp. (NYSEAMERICAN: BTG)’s stock price stands at 4.9800 At close: 4:00PM EDT, April 15. The opening price was 4.7800 and the previous closing price, as of April 14, was 4.6800. The price increased by 0.3000. Day’s range- 4.7700 – 5.0222.

B2Gold Corp. (NYSEAMERICAN: BTG)’s stock price is currently at the month’s highest. The highest price of the day(April 15)  was 5.0200 and the lowest was 4.7700. 

B2Gold is a low-cost international senior gold producer headquartered in Vancouver, Canada. Founded in 2007, today, B2Gold has operating gold mines in Mali, Namibia and the Philippines and numerous exploration and development projects in various countries including Mali and Colombia. B2Gold continues to forecast total consolidated gold production of between 970,000 and 1,030,000 ounces in 2021. 

Mine-by-mine gold production in the first quarter of 2021 (including the Company’s estimated 33% share of Calibre’s production) was as follows:

Mine Q1 2021

Gold Production

(ounces)

First-Half 2021

Forecast

Gold Production

(ounces)

Second-Half

2021 Forecast

Gold Production

(ounces)

Full-year

2021 Forecast

Gold Production

(ounces)

Fekola 125,088 220,000 – 230,000 310,000 – 330,000 530,000 – 560,000
Masbate 57,513 100,000 – 105,000 100,000 – 105,000 200,000 – 210,000
Otjikoto 23,042 45,000 – 50,000 145,000 – 150,000 190,000 – 200,000
B2Gold Consolidated (1) 205,643 365,000 – 385,000 555,000 – 585,000 920,000 – 970,000
Equity interest in Calibre (2) 15,001 25,000 – 30,000 25,000 – 30,000 50,000 – 60,000
Total 220,644 390,000 – 415,000 580,000 – 615,000 970,000 – 1,030,000

 

1 “B2Gold Consolidated” – gold production is presented on a 100% basis, as B2Gold fully consolidates the results of its Fekola, Masbate and Otjikoto mines in its consolidated financial statements (even though it does not own 100% of these operations).
2 “Equity interest in Calibre” – represents the Company’s approximate 33% indirect share of the operations of Calibre’s El Limon and La Libertad mines. B2Gold applies the equity method of accounting for its 33% ownership interest in Calibre.
Continue Reading

Market News

HBM Stock Price Increased By 6.72%: Here’s What Happened

Published

on

Hudbay Minerals Inc. (NYSE: HBM)’s stock price currently stands at 8.42, as of April 15, 4:00PM EDT, market close. The previous closing price was 7.89(April 14). Thus, a surge of 6.72% is significant. The day’s range was between 7.98 – 8.51. 

Hudbay (NYSE: HBM) is a diversified mining company primarily producing copper concentrate (containing copper, gold and silver) and zinc metal. Hudbay (NYSE: HBM)’s stock price is grossing at its highest price of this month, the second highest price being 8.06( Closing price April 8).

Hudbay Minerals Inc. (NYSE: HBM) today announced that the final land user agreement for Pampacancha has been completed and Hudbay now has full access to the site to begin pit development activities.

“We are very pleased to have completed the final land user agreements at Pampacancha and we remain on track for first production in the second quarter of 2021, in line with guidance,” said Peter Kukielski, Hudbay’s President and Chief Executive Officer. “This major milestone was achieved due to collaboration between the community and the Constancia team, which further demonstrates Hudbay’s strong social license to operate in Peru.”

In January 2021, the company commenced pre-development activities, including haul road construction and site preparation work, which will allow Hudbay to commence pre-stripping activities shortly. Pampacancha is a high-grade copper and gold satellite deposit located approximately seven kilometres from Hudbay’s Constancia mine and processing facilities in Peru. Pampacancha is expected to contribute to an increase in copper and gold production at Constancia from 2022 to 2025 as the higher grades enter into the mine plan.

Continue Reading

Trending